Analyst consensus rating
Cognition Therapeutics Analyst Rating: Strong Buy
CGTX is rated Strong Buy by 3 analysts with a $3.33 target. As of 2026-08-27.
Direct answer
Cognition Therapeutics's consensus rating is Strong Buy.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $3.33.
Forecast evidence checked August 27, 2026.
Get free Cognition Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.05
- Average price target
- $3.33
- High price target
- $4.00
- Low price target
- $3.00
- Low target gap
- +185.7%
- Target upside
- +217.5%
- High target gap
- +281%
- Target range width
- 95.2%
- Consensus rating
- Strong Buy
- Analysts
- 3
- Evidence date
- August 27, 2026
- Valid through
- September 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Cognition Therapeutics?
Cognition Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $3.33.
How far are Cognition Therapeutics's low and high targets from the recorded price?
The low target implies +185.7%, while the high target implies +281%.
How many analysts are included in Cognition Therapeutics's consensus?
The verified consensus includes 3 analysts.
How is Cognition Therapeutics's target upside or downside calculated?
The average target of $3.33 is divided by the recorded price of $1.05, then one is subtracted to produce +217.5%. This does not guarantee a future return.
When was Cognition Therapeutics's analyst forecast verified?
The data was verified on 2026-08-27. The dataset is valid through 2026-09-03.